FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
WHY IT MATTERS
Patients with advanced pancreatic cancer who have exhausted standard treatment options may now have access to daraxonrasib through expanded access, potentially offering a new therapeutic option while the drug completes its clinical development.
The FDA has given approval for Revolution Medicines to offer an experimental pancreatic cancer drug called daraxonrasib to patients outside of clinical trials through a special program called expanded access. This program allows patients with serious illnesses who have no other treatment options to try investigational drugs before they are fully approved. This is an important step forward for patients with pancreatic cancer who may benefit from this new treatment.
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
ASK YOUR DOCTOR
If you or a loved one has pancreatic cancer, ask your oncologist whether daraxonrasib expanded access might be appropriate and how to inquire about eligibility with Revolution Medicines.